Navigation Links
SALVAT Announces Submission of Complete Response to FDA Approvable Letter for CETRAXAL(R)
Date:11/5/2008

BARCELONA, Spain, November 5 /PRNewswire/ -- SALVAT announced today the submission of the response to the FDA Approvable Letter for CETRAXAL(R) (Ciprofloxacin 0.2% Otic Solution in Single Dose Containers). In an Approvable Letter received on April 6, 2006, the FDA requested additional data with respect to chemistry, manufacturing, and controls (CMC).

SALVAT expects the FDA to classify the complete response as a Class 2 resubmission, under which the FDA will seek to complete its review of the resubmission within 180 days from the time of resubmission. SALVAT believes that the response submitted today to the FDA fully addresses the Agency request.

The Approvable Letter did not raise any questions related to efficacy or safety of CETRAXAL(R) Otic Solution.

SALVAT is currently evaluating potential commercial partners in the United States to licensing out CETRAXAL(R) and expects to launch it during the second quarter of 2009, subject to FDA approval.

The NDA for CETRAXAL(R) seeks marketing approval for the treatment of Acute Otitis Externa in pediatric (aged 1 year and older) and adult patients.

About CETRAXAL(R)

CETRAXAL(R) is a Ciprofloxacin 0.2% Otic Solution for the treatment of Acute Otitis Externa. In a phase III clinical trial compared to Neomycin, Polymyxin B sulfates and Hydrocortisone otic solution (NPH), CETRAXAL(R) obtained a clinical cure rate of 93.9% in pediatric patients (vs. 76.0% in the NPH group) and resolved or improved otalgia in 99.2% of the patients. There were no adverse reactions with an incidence higher than 1%. CETRAXAL(R) will be available in sterile, preservative-free single-dose containers which make easy to ensure correct dosing and to place drops into the ear.

About SALVAT

SALVAT is an independent, privately owned, Spanish pharmaceutical group closely identified with technological innovation and strongly committed to R&D. The most advanced NCE is SVT-40776 for the treatment of
'/>"/>

SOURCE SALVAT
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. SALVAT has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776 for the Treatment of Overactive Bladder
2. Telik Announces Financial Results for 2008 Third Quarter
3. Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress
4. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
5. Assay Designs(TM), Inc. Announces Agreement with Abnova Corp. of Taiwan
6. Environmental Tectonics Corporation Announces Staff Addition to Its BioMedical Systems Division
7. Misonix Announces New Distribution Agreement for The Netherlands
8. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
9. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
10. China Sky One Medical, Inc. Announces Conference Call to Discuss Third Quarter 2008 Results
11. Oncolytics Biotech Inc. Announces 2008 Third Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 This webinar will focus on ... safety assessment in biosimilars. , Regulatory frameworks are evolving ... development, however the complex nature of biopharmaceuticals makes the ... efficacy extremely challenging. Based on the specific aspects of ...
(Date:1/15/2014)... DTS Language Services, Inc . is ... for Life Science organizations who need document translations. Clients ... of their documents in advance with a selection of nearly ... translations, often a critical factor in clinical and scientific fields, ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... and Brent Butler 2 , ... Massachusetts, USA , ... , Introduction , ... carried out using manual pipetting. As the demand for greater throughput of plate ...
... , , , , FLEXSTATION IS A ... SIMPLE, RAPID EXPERIMENTAL SET-UP AND DATA ANALYSIS , , ... , EXCELLENT FOR ASSAY DEVELOP-MENT AS DEMONSTRATED BY Z FACTOR ... G q -coupled receptors are transmembrane proteins that are responsible ...
... , HOMOGENEOUS ASSAY , , ... PROCEDURE , , COMPATIBLE WITH MORE TARGETS ... , The ... detecting changes,in intracellular calcium concentration.,Specifically, this fast and simple fluorescencebased,assay allows the ...
Cached Biology Technology:96 Well Pipetting Precision and Accuracy Using the RapidPlate 96/384 Workstation 296 Well Pipetting Precision and Accuracy Using the RapidPlate 96/384 Workstation 396 Well Pipetting Precision and Accuracy Using the RapidPlate 96/384 Workstation 4Gq-coupled receptor assays using FLEXstation: M1 muscarinic receptor 2Gq-coupled receptor assays using FLEXstation: M1 muscarinic receptor 3Gq-coupled receptor assays using FLEXstation: M1 muscarinic receptor 4Calcium Plus Assay Kit, Superior Detection for Specialized Targets 2Calcium Plus Assay Kit, Superior Detection for Specialized Targets 3
(Date:4/23/2014)... of Public Health-Bloomington has bolstered the link between red ... association between heme iron, found only in meat, and ... that heme iron consumption increased the risk for coronary ... found between nonheme iron, which is in plant and ... study was published online ahead of print in the ...
(Date:4/23/2014)... Toronto Scarborough research shows that male black widow spiders ... a rare example of mate preference by male spiders. ... Emily MacLeod and Maydianne Andrade, a professor in UTSC,s ... studies and the wild that males overwhelmingly chose to ... black widows can tell whether a potential mate is ...
(Date:4/23/2014)... the likelihood of an accurate group decision increases with ... when a collective faces a variety of factors ... University researchers report that smaller groups actually tend to ... excessively focused on only certain pieces of information. , ... known about collective intelligence, or the "wisdom of crowds," ...
Breaking Biology News(10 mins):Study: Iron consumption can increase risk for heart disease 2Picky male black widow spiders prefer well-fed virgins 2Too many chefs: Smaller groups exhibit more accurate decision-making 2Too many chefs: Smaller groups exhibit more accurate decision-making 3
... Va. The availability of new genome sequencing ... to test an intriguing hypothesis about how agricultures ... plant pathogens. Boris Vinatzer, assistant professor of ... College of Agriculture and Life Sciences, has received ...
... GAINESVILLE, Fla. Using the genetic equivalent of an ... the Earth endured a massive cooling period between 500 ... (Feb. 7) in the journal Nature, researchers from the ... and the biotechnology company DNA2.0 describe how they reconstructed ...
... YORK (FEBRUARY 7, 2008) Madagascars turtles and tortoises, ... will continue to crawl steadily toward extinction unless major ... by the Wildlife Conservation Society and other groups. ... capital city Antananarivo, said there is still hope to ...
Cached Biology News:Tomato pathogen genome may offer clues about bacterial evolution at dawn of agriculture 2Scientists rebuild ancient proteins to reveal primordial Earth's temperature 2Madagascar's tortoises are crawling toward extinction, groups say 2
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
...
... OrientExpress™ System Modules ... synthesis and directional cloning ... T7 expression vectors ... configuring OrientExpress™ Cloning Systems, ...
... and antibody-based immunoaffinity matrices, such as ... times without compromising antigen-antibody reactivity, the ... agents has precluded the application of ... The CHEMICON Re-Blot Plus Western Blot ...
Biology Products: